Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why Switzerland will continue to play a vital role in Biogen’s global clinical research footprint, and some of the country’s market access and pricing challenges. Dr Gasser also highlights Biogen’s burgeoning biosimilars portfolio and the importance of diversity in the workplace.
We are happy and proud to be pioneers in neuroscience, but our pioneering work also requires us to keep pace with an increasingly ambiguous and changing environment to ensure that patients have access to our breakthrough therapies
